[{"id":"b11c3dd5-a7d2-45b9-88bd-188586703589","acronym":"","url":"https://clinicaltrials.gov/study/NCT07190248","created_at":"2025-09-27T08:39:58.068Z","updated_at":"2025-09-27T08:39:58.068Z","phase":"Phase 3","brief_title":"A Clinical Study of MK-1084 and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)","source_id_and_acronym":"NCT07190248","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1 • KRAS","pipe":"","alterations":" ","tags":["PD-L1 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • calderasib (MK-1084)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 675","initiation":"Initiation: 10/27/2025","start_date":" 10/27/2025","primary_txt":" Primary completion: 12/07/2029","primary_completion_date":" 12/07/2029","study_txt":" Completion: 08/06/2032","study_completion_date":" 08/06/2032","last_update_posted":"2025-09-24"},{"id":"7ee22b9c-eea6-45ba-bdc2-0adfd9a6a3e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT07174908","created_at":"2025-09-20T07:06:19.138Z","updated_at":"2025-09-20T07:06:19.138Z","phase":"Phase 3","brief_title":"A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation","source_id_and_acronym":"NCT07174908","lead_sponsor":"InxMed (Shanghai) Co., Ltd.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • pemetrexed • Anfangning (garsorasib) • ifebemtinib (IN10018)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 09/01/2030","study_completion_date":" 09/01/2030","last_update_posted":"2025-09-16"},{"id":"27751dcd-f28f-4f36-b8db-e4042ae9fc77","acronym":"CVL006-T1002","url":"https://clinicaltrials.gov/study/NCT07157956","created_at":"2025-09-13T08:47:52.158Z","updated_at":"2025-09-13T08:47:52.158Z","phase":"Phase 1/2","brief_title":"CVL006 Combination Therapy in Advanced Solid Tumors","source_id_and_acronym":"NCT07157956 - CVL006-T1002","lead_sponsor":"Convalife (Shanghai) Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Enhertu (fam-trastuzumab deruxtecan-nxki) • pemetrexed • Padcev (enfortumab vedotin-ejfv) • Jiataile (sacituzumab tirumotecan)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 318","initiation":"Initiation: 09/10/2025","start_date":" 09/10/2025","primary_txt":" Primary completion: 08/12/2028","primary_completion_date":" 08/12/2028","study_txt":" Completion: 12/30/2028","study_completion_date":" 12/30/2028","last_update_posted":"2025-09-05"},{"id":"95dd2ce0-ed59-4a61-b9b8-24f3c51885f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT07020065","created_at":"2025-06-14T13:53:41.046Z","updated_at":"2025-06-14T13:53:41.046Z","phase":"Phase 2","brief_title":"Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 \u003c50%","source_id_and_acronym":"NCT07020065","lead_sponsor":"Swiss Group for Clinical Cancer Research","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • paclitaxel • pemetrexed • Libtayo (cemiplimab-rwlc)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 11/01/2025","start_date":" 11/01/2025","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 03/01/2030","study_completion_date":" 03/01/2030","last_update_posted":"2025-06-13"},{"id":"c6f24729-d5a7-4244-ad7f-a2cffb7113b4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06917079","created_at":"2025-06-07T14:12:37.863Z","updated_at":"2025-06-07T14:12:37.863Z","phase":"Phase 1","brief_title":"BBO-11818 in Adult Subjects With KRAS Mutant Cancer","source_id_and_acronym":"NCT06917079","lead_sponsor":"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 287","initiation":"Initiation: 03/31/2025","start_date":" 03/31/2025","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 09/01/2029","study_completion_date":" 09/01/2029","last_update_posted":"2025-06-06"},{"id":"0d632197-009b-4cc8-8b15-f154cec2fe79","acronym":"ACCIO","url":"https://clinicaltrials.gov/study/NCT04267848","created_at":"2021-01-18T20:44:14.334Z","updated_at":"2025-02-25T12:37:33.994Z","phase":"Phase 3","brief_title":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial","source_id_and_acronym":"NCT04267848 - ACCIO","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["EGFR • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • pemetrexed • Pembroria (pembrolizumab biosimilar) • liposomal gemcitabine (FF-10832)"],"overall_status":"Recruiting","enrollment":" Enrollment 1210","initiation":"Initiation: 06/16/2020","start_date":" 06/16/2020","primary_txt":" Primary completion: 12/15/2025","primary_completion_date":" 12/15/2025","study_txt":" Completion: 12/15/2025","study_completion_date":" 12/15/2025","last_update_posted":"2025-02-24"},{"id":"0db89e9b-db2b-43cc-83d7-77deb9d111cd","acronym":"SCOUT","url":"https://clinicaltrials.gov/study/NCT02637687","created_at":"2021-01-17T17:20:37.992Z","updated_at":"2025-02-25T12:26:24.234Z","phase":"Phase 1/2","brief_title":"A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children","source_id_and_acronym":"NCT02637687 - SCOUT","lead_sponsor":"Bayer","biomarkers":" NTRK3 • ETV6 • NTRK","pipe":" | ","alterations":" NTRK positive • NTRK fusion","tags":["NTRK3 • ETV6 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK positive • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Vitrakvi (larotrectinib) • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 154","initiation":"Initiation: 12/16/2015","start_date":" 12/16/2015","primary_txt":" Primary completion: 07/20/2024","primary_completion_date":" 07/20/2024","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-24"},{"id":"3c07681e-1c58-4557-8010-1fc74e4cbe8d","acronym":"KRYSTAL-7","url":"https://clinicaltrials.gov/study/NCT04613596","created_at":"2021-01-19T20:33:04.646Z","updated_at":"2025-02-25T12:27:47.978Z","phase":"Phase 2/3","brief_title":"Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7","source_id_and_acronym":"NCT04613596 - KRYSTAL-7","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" PD-L1 • KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["PD-L1 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Krazati (adagrasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 806","initiation":"Initiation: 12/02/2020","start_date":" 12/02/2020","primary_txt":" Primary completion: 10/31/2028","primary_completion_date":" 10/31/2028","study_txt":" Completion: 10/31/2029","study_completion_date":" 10/31/2029","last_update_posted":"2025-02-24"},{"id":"ca7e4b34-6f76-4ea3-8c6b-e39973324752","acronym":"NRG-LU003","url":"https://clinicaltrials.gov/study/NCT03737994","created_at":"2023-11-21T21:15:46.432Z","updated_at":"2025-02-25T12:37:11.248Z","phase":"Phase 2","brief_title":"Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03737994 - NRG-LU003","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET","pipe":" | ","alterations":" ALK positive • MET amplification • ALK rearrangement","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • MET amplification • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • carboplatin • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Ensacove (ensartinib) • Pemfexy (pemetrexed)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 07/25/2019","start_date":" 07/25/2019","primary_txt":" Primary completion: 07/21/2021","primary_completion_date":" 07/21/2021","study_txt":" Completion: 12/02/2025","study_completion_date":" 12/02/2025","last_update_posted":"2025-02-24"},{"id":"d4921ecb-dbf8-4a8b-a82b-331ac066876f","acronym":"ACHIEVE Study","url":"https://clinicaltrials.gov/study/NCT06096844","created_at":"2023-10-24T15:13:40.333Z","updated_at":"2025-02-25T12:38:45.622Z","phase":"Phase 3","brief_title":"Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial","source_id_and_acronym":"NCT06096844 - ACHIEVE Study","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" ALK translocation • EGFR negative","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK translocation • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 304","initiation":"Initiation: 07/19/2024","start_date":" 07/19/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-24"},{"id":"e3b4bad8-8656-47cc-998e-a5d2146657b6","acronym":"ALCHEMIST Screening","url":"https://clinicaltrials.gov/study/NCT02194738","created_at":"2021-01-18T10:15:39.910Z","updated_at":"2025-02-25T12:26:10.714Z","phase":"","brief_title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","source_id_and_acronym":"NCT02194738 - ALCHEMIST Screening","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • ALK • PIK3CA • PTEN • PD-1 • CTLA4","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement","tags":["EGFR • PD-L1 • ALK • PIK3CA • PTEN • PD-1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Lynparza (olaparib) • cisplatin • Xalkori (crizotinib) • erlotinib • carboplatin • gemcitabine • paclitaxel • docetaxel • Mektovi (binimetinib) • pemetrexed • sapanisertib (CB-228) • Zaltrap (ziv-aflibercept IV) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed) • liposomal gemcitabine (FF-10832)"],"overall_status":"Recruiting","enrollment":" Enrollment 8300","initiation":"Initiation: 09/26/2014","start_date":" 09/26/2014","primary_txt":" Primary completion: 09/28/2026","primary_completion_date":" 09/28/2026","study_txt":" Completion: 09/28/2026","study_completion_date":" 09/28/2026","last_update_posted":"2025-02-24"},{"id":"111c1a17-fe9b-4de2-8802-129cd4e4d500","acronym":"LEAP-006","url":"https://clinicaltrials.gov/study/NCT03829319","created_at":"2021-01-17T17:11:51.730Z","updated_at":"2025-02-25T13:35:12.715Z","phase":"Phase 3","brief_title":"Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)","source_id_and_acronym":"NCT03829319 - LEAP-006","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • Lenvima (lenvatinib) • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 761","initiation":"Initiation: 03/25/2019","start_date":" 03/25/2019","primary_txt":" Primary completion: 08/11/2023","primary_completion_date":" 08/11/2023","study_txt":" Completion: 08/30/2024","study_completion_date":" 08/30/2024","last_update_posted":"2025-02-21"},{"id":"9272430e-eab6-4fc0-8844-69d711337ecc","acronym":"ENDURE","url":"https://clinicaltrials.gov/study/NCT04892953","created_at":"2021-05-19T15:52:50.047Z","updated_at":"2025-02-25T13:40:30.743Z","phase":"Phase 2","brief_title":"Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy","source_id_and_acronym":"NCT04892953 - ENDURE","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR • ALK • MET • RET • ROS1","pipe":" | ","alterations":" RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 rearrangement • RET rearrangement","tags":["EGFR • ALK • MET • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 rearrangement • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 07/07/2021","start_date":" 07/07/2021","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-21"},{"id":"a672992d-19fb-49b7-9557-516b222cb23a","acronym":"ARTEMIDE-Lung03","url":"https://clinicaltrials.gov/study/NCT06627647","created_at":"2025-02-25T13:36:39.041Z","updated_at":"2025-02-25T13:36:39.041Z","phase":"Phase 3","brief_title":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC","source_id_and_acronym":"NCT06627647 - ARTEMIDE-Lung03","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • rilvegostomig (AZD2936)"],"overall_status":"Recruiting","enrollment":" Enrollment 878","initiation":"Initiation: 11/27/2024","start_date":" 11/27/2024","primary_txt":" Primary completion: 05/10/2029","primary_completion_date":" 05/10/2029","study_txt":" Completion: 03/25/2030","study_completion_date":" 03/25/2030","last_update_posted":"2025-02-21"},{"id":"09e74a0b-2911-4165-9b8f-e77d19ed6b2f","acronym":"TroFuse-004","url":"https://clinicaltrials.gov/study/NCT06074588","created_at":"2023-10-10T14:11:53.919Z","updated_at":"2025-02-25T13:49:58.239Z","phase":"Phase 3","brief_title":"Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)","source_id_and_acronym":"NCT06074588 - TroFuse-004","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • BRAF","pipe":" | ","alterations":" EGFR mutation • EGFR T790M","tags":["EGFR • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • pemetrexed • Jiataile (sacituzumab tirumotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 556","initiation":"Initiation: 11/12/2023","start_date":" 11/12/2023","primary_txt":" Primary completion: 05/10/2027","primary_completion_date":" 05/10/2027","study_txt":" Completion: 03/11/2030","study_completion_date":" 03/11/2030","last_update_posted":"2025-02-20"},{"id":"ce9dfb12-840f-46f6-b8d1-947639822665","acronym":"Morpheus Lung","url":"https://clinicaltrials.gov/study/NCT03337698","created_at":"2021-01-18T16:29:17.212Z","updated_at":"2025-02-25T13:48:26.615Z","phase":"Phase 1/2","brief_title":"A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)","source_id_and_acronym":"NCT03337698 - Morpheus Lung","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • docetaxel • Cotellic (cobimetinib) • pemetrexed • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • Repatha (evolocumab) • camonsertib (RP-3500) • cibisatamab (RG7802) • ciforadenant (CPI-444) • zanzalintinib (XL092)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 314","initiation":"Initiation: 12/27/2017","start_date":" 12/27/2017","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2025-02-20"},{"id":"29707765-41ef-4904-94a6-cabf9f766606","acronym":"IMpower030","url":"https://clinicaltrials.gov/study/NCT03456063","created_at":"2021-01-18T17:02:24.865Z","updated_at":"2025-02-25T14:01:22.616Z","phase":"Phase 3","brief_title":"A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)","source_id_and_acronym":"NCT03456063 - IMpower030","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":" | ","alterations":" IRF1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IRF1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 453","initiation":"Initiation: 04/24/2018","start_date":" 04/24/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-19"},{"id":"6b56b2f0-6f31-45d1-8ab6-6477c5f17c19","acronym":"RELATIVITY-1093","url":"https://clinicaltrials.gov/study/NCT06561386","created_at":"2025-02-25T14:04:42.242Z","updated_at":"2025-02-25T14:04:42.242Z","phase":"Phase 3","brief_title":"A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%","source_id_and_acronym":"NCT06561386 - RELATIVITY-1093","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • carboplatin • pemetrexed • Opdualag (nivolumab/relatlimab-rmbw)"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 10/07/2024","start_date":" 10/07/2024","primary_txt":" Primary completion: 07/30/2030","primary_completion_date":" 07/30/2030","study_txt":" Completion: 11/11/2033","study_completion_date":" 11/11/2033","last_update_posted":"2025-02-19"},{"id":"be73eee7-8633-483e-a581-812fd81e01b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04929041","created_at":"2021-06-18T23:52:29.992Z","updated_at":"2025-02-25T14:02:22.824Z","phase":"Phase 2/3","brief_title":"Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative","source_id_and_acronym":"NCT04929041","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • ALK mutation","tags":["EGFR • PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • albumin-bound paclitaxel • pemetrexed • ABP 206 (nivolumab biosimilar) • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 427","initiation":"Initiation: 10/07/2022","start_date":" 10/07/2022","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-19"},{"id":"ca63580a-c74e-4b79-b0d5-8d419247f75b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03177291","created_at":"2021-01-18T15:40:02.831Z","updated_at":"2025-02-25T14:15:00.298Z","phase":"Phase 1","brief_title":"Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC","source_id_and_acronym":"NCT03177291","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • albumin-bound paclitaxel • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 09/26/2017","start_date":" 09/26/2017","primary_txt":" Primary completion: 05/09/2021","primary_completion_date":" 05/09/2021","study_txt":" Completion: 12/04/2024","study_completion_date":" 12/04/2024","last_update_posted":"2025-02-18"},{"id":"2b60e541-1e3c-4090-9044-9dd28f2e4baf","acronym":"A092001","url":"https://clinicaltrials.gov/study/NCT05001880","created_at":"2023-11-29T23:15:50.240Z","updated_at":"2025-02-25T14:16:16.072Z","phase":"Phase 2","brief_title":"Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma","source_id_and_acronym":"NCT05001880 - A092001","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSLN","pipe":"","alterations":" ","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • pemetrexed • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 03/22/2022","start_date":" 03/22/2022","primary_txt":" Primary completion: 08/20/2025","primary_completion_date":" 08/20/2025","study_txt":" Completion: 08/20/2025","study_completion_date":" 08/20/2025","last_update_posted":"2025-02-17"},{"id":"ac98599e-66be-47cf-ae0f-233b9edd3aa9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06405230","created_at":"2024-05-08T20:30:26.111Z","updated_at":"2025-02-25T14:19:04.825Z","phase":"Phase 1/2","brief_title":"Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Patient-derived Organoids and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT06405230","lead_sponsor":"GlaxoSmithKline","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Jemperli (dostarlimab-gxly)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/28/2025","start_date":" 02/28/2025","primary_txt":" Primary completion: 12/16/2027","primary_completion_date":" 12/16/2027","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2025-02-17"},{"id":"ba447789-4a4c-4ec5-9b94-2dc570638807","acronym":"","url":"https://clinicaltrials.gov/study/NCT03647098","created_at":"2021-01-18T17:54:08.057Z","updated_at":"2025-02-25T14:40:00.663Z","phase":"","brief_title":"Survival Outcomes of Lung Cancer","source_id_and_acronym":"NCT03647098","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 20000","initiation":"Initiation: 08/01/2018","start_date":" 08/01/2018","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-02-14"},{"id":"cd480536-5f7e-444d-af5e-6fed1b7c13bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04410796","created_at":"2021-01-18T21:16:01.585Z","updated_at":"2025-02-25T14:40:36.515Z","phase":"Phase 2","brief_title":"Osimertinib Alone or with Chemotherapy for EGFR-Mutant Lung Cancers","source_id_and_acronym":"NCT04410796","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • carboplatin • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 571","initiation":"Initiation: 05/28/2020","start_date":" 05/28/2020","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2025-02-14"}]